Applied Molecular Transport: AMT Corporate Presentation July 2022
This presentation and any accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and management’s objectives for future operations, as well as that
as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “estimate”, “intend”, “may”, “may”, “plan”, “potential”, “target”. , “will”, “mission”. ” or the negative form of these terms or other similar expressions.
We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These statements include, but are not limited to, the potential and expectations regarding the potential, the potential benefits and expectations regarding AMT’s technology platform, AMT-101 and AMT-126, statements regarding the potential for market for AMT’s product candidates, statements regarding AMT’s Phase 2 clinical trials for AMT-101 and AMT’s Phase 1 clinical trials for AMT-126, including the timing of such trials, recruitment of these trials, milestones and expectations regarding the reading of data from these clinical trials, and AMT’s ability to leverage its technology to expand its pipeline, including our ability to expand our technology platform by developing therapies to treat respiratory diseases. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among others: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and programs of research ; our ability to use and expand our technology platform to build a pipeline of product candidates; uncertainty about the development of biological therapies; our ability to advance product candidates into and successfully complete clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we target and the number of patients likely to participate in our clinical trials; the commercialization of our product candidates, if approved; our ability and potential to successfully manufacture and supply our product candidates for clinical trials and for commercial purposes, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenues, capital requirements and additional financing needs and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure needs; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our businesses and product candidates; the extent of protection we are able to establish and maintain for intellectual property rights, including our technology platform, product candidates and research programs; our ability to enter into contracts with third-party suppliers and manufacturers and their ability to operate adequately; pricing, coverage and reimbursement of our product candidates, if approved; developments related to our competitors and our industry, including competing product candidates and therapies; the negative impacts of the COVID-19 pandemic on our operations; and other risks. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors. Actual results may differ materially from those in the forward-looking statements due to a number of factors, including those described in the company’s filings with the Securities and Exchange Commission. You should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this presentation.
This presentation also contains estimates and other statistical data made by independent parties and by us regarding market size and growth and other data about our industry. These data involve a number of assumptions and limitations, and you are cautioned not to place undue weight on these estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
This presentation concerns product candidates that are under clinical investigation and have not yet been approved for marketing by the US Food and Drug Administration (FDA). These product candidates are currently limited by federal law to experimental use, and no representation is made as to their safety or effectiveness for the purposes for which they are investigated.